Short-term Interferon-alfa Therapy for Acute Hepatitis C: A Randomized Controlled Trial

Hepatology

Volumn 39, Issue 5, 2004, Pages 1213-1219

  Nomura, Hideyuki ^a,f   Sou, Suketo ^a   Tanimoto, Hironori ^a   Nagahama, Takashi ^a   Kimura, Yoichi ^b   Hayashi, Jun ^c   Ishibashi, Hiromi ^d   Kashiwagi, Seizaburo ^e  

^a Shin Kokura Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^e Japanese Red Cross Kyushu Block Blood Center   (Japan)

^f Shin Kokura Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HUMAN LYMPHOBLASTOID INTERFERON; UNCLASSIFIED DRUG;

ACUTE DISEASE; ACUTE HEPATITIS; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; VIROLOGY;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 2342533783     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20196     Document Type: Article

References (22)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;22:825-832.
2. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. HEPATOLOGY 1995;21:650-655.
3. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;15:1452-1457.
4. Hofer H, Watkins-Riedel T, Janata O, Penner E, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. HEPATOLOGY 2003;37;60-64.
5. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-88.
6. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. HEPATOLOGY 1999;29:1124-1130.
7. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. HEPATOLOGY 1998;27:1394-1402.
8. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. HEPATOLOGY 2003;38:493-502.
9. Arif A, Levine RA, Sanderson SO, Bank L, Velu RP, Shah A, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003;48:1425-1430.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;26:975-982.
11. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
12. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, et al. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991;338:914-915.
13. Viladomiu L, Genesca J, Esteban JI, Allende H, Gonzalez A, Lopez-Talavera JC, et al, Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. HEPATOLOGY 1992;15:767-769.
14. Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective randomized, controlled-dose study. Gastroenterology 1994;107:805-811.
15. Lampertico P, Rumi M, Romeo R, Craxi A, Soffredini R, Biassoni D, et al. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. HEPATOLOGY 1994;19:19-22.
16. Hwang SJ, Lee SD, Chan CY, Lu RH, Lo KJ.A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J Hepatol 1994;21:831-836.
17. Ohnishi K, Nomura F, Nakano M. Interferon therapy for acute post-transfusion non-A, non-B hepatitis: response with respect to anti-hepatitis C virus antibody status. Am J Gastroenterol 1991;86:1041-1049.
18. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C virus genotypes. HEPATOLOGY 1994;19:1321-1324.
19. Oketani M, Higashi T, Yamasaki N, Shinmyozu K, Osame M, Arima T. Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick. J Clin Gastroenterol 1999;28:49-51.
20. Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001;358:1241-1242.
21. Nomura H, Kimura Y, Morita C, Tada H, Okamoto O, Shiraishi G, et al. Usefulness of HCV-RNA assays in efficacy evaluation of interferon treatment for chronic hepatitis C: Amplicor HCV assay and branched DNA probe assay. J Infect 1997;34:349-355.
22. Yamaji K, Hayashi J, Kawakami Y, Furusyo N, Sawayama Y, Kishihara Y, et al. Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response. J Clin Gastroenterol 1998;26:193-199.